Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00278525
Recruitment Status : Completed
First Posted : January 18, 2006
Results First Posted : April 30, 2014
Last Update Posted : April 30, 2014
Information provided by (Responsible Party):
Richard Burt, MD, Northwestern University

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Interventions: Drug: standard of care
Procedure: stem cell transplantation

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations

Eligible (n=19) Randomized (n=19)

  1. Allocated to Hematopoietic Stem Cell Transplantation (HSCT (n=10) + crossed over to HSCT(n=7)

    • Received HSCT (n=17); Lost to follow-up (n=0); Analysed (n=17)

  2. Allocated to cyclophosphamide (n=9) • Received allocated intervention (n=9) Lost to follow-up (n=0); Crossed over (n=7); Analysed (n=9)

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Standard of Care Cyclophosphamide will be given as approved immunosuppressive therapy
Stem Cell Trasplantation intervention as stem cell transplantation after conditioning regimen

Participant Flow:   Overall Study
    Standard of Care   Stem Cell Trasplantation
STARTED   9   10 
COMPLETED   9 [1]   10 [2] 
[1] 7 participants crossed to HSCT arm in accordance with the protocol
[2] 7 participant crossed over to the HSCT arm and underwent HSCT, in accordance with the protocol.

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Stem Cell Trasplantation intervention as stem cell transplantation after conditioning regimen
Standard of Care medication as standard of care will be given
Total Total of all reporting groups

Baseline Measures
   Stem Cell Trasplantation   Standard of Care   Total 
Overall Participants Analyzed 
[Units: Participants]
 10   9   19 
[Units: Participants]
<=18 years   0   0   0 
Between 18 and 65 years   10   9   19 
>=65 years   0   0   0 
[Units: Years]
Mean (Standard Deviation)
 45  (13)   44  (10)   44  (10) 
[Units: Participants]
Female   10   8   18 
Male   0   1   1 
Region of Enrollment 
[Units: Participants]
United States   10   9   19 

  Outcome Measures

1.  Primary:   Time to Treatment Failure   [ Time Frame: 12 months ]

2.  Primary:   Disease Improvement   [ Time Frame: 12 months ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:  
Name/Title: Dr. Richard Burt
Organization: Northwestern University
phone: 312-908-0059

Publications automatically indexed to this study by Identifier (NCT Number):

Responsible Party: Richard Burt, MD, Northwestern University Identifier: NCT00278525     History of Changes
Other Study ID Numbers: DI Scl.Randomized2004
First Submitted: January 15, 2006
First Posted: January 18, 2006
Results First Submitted: April 9, 2013
Results First Posted: April 30, 2014
Last Update Posted: April 30, 2014